31 results about "Hematologic disorders" patented technology

Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.

The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.

The invention discloses a kit for quantitatively detecting IKZF1 gene mutation. The kit for quantitatively detecting the IKZF1 gene mutation consists of a primer pair and a probe, wherein a primer sequence of the primer pair is shown as SEQ ID No:1; the other primer sequence is shown as SEQ ID No:2; and the sequence of the probe is shown as SEQ ID No:3. The primer pair and the probe can be used for quantitatively detecting the IKZF1 gene mutation level, and the kit is easy, convenient and sensitive, so that the kit is used for auxiliary diagnosis, MRD (Minimal Residual Disease) monitoring, prognostic evaluation and the like on neoplastic hematologic disorder patients (particularly ALL leukemia patients and CML patients) and has significance in the field of medical detection.

The invention discloses a human-derived CD-19 chimeric antigen receptor T lymphocyte vector which is characterized by comprising a plasmid vector for coding single-chain variable region genes of CD19monoclonal antibodies, nucleosomal histone monoclonal antibodies and FNEDB monoclonal antibodies. The vector is a lentiviral vector. The invention further discloses application of the human-derived CD-19 chimeric antigen receptor T lymphocyte vector in preparation of CATR cells. The vector is used for transduction of T lymphocytes, natural killer cells and mononuclear cells, and is applied to treating tumors, preferably treating reoccurrence in malignant lymphoma drugs as well as neoplastic hematologic disorders and lymphomas which are refractory and unsuccessful in bone marrow transplantationmatching. The human-derived CD-19 chimeric antigen receptor T lymphocyte vector disclosed by the invention has the beneficial effects that the vector constructed in the invention can achieve the effects of enhancing the targeted CD19 antigen transgenic T lymphocyte specificity, overcoming the tumor microenvironment inhibited immune cellular function and controlling cytokine storm in clinic treatment.

The invention provides a method for leukaemia high-flux medicine screening. The method comprises the following steps of performing separation, extraction, identification and culture on neoplastic hematologic disorder stem cells: performing acquisition on bone marrow samples, performing separation on mononuclear cells, performing separation on leukaemia stem cell groups through an immunomagnetic bead method; and performing subculturing on the cells after separation and purification of magnetic beads; and establishing a medicine library: according to a medicine description and pharmacokinetics,selecting the concentration of medicines, performing mixed culture on the medicines and the neoplastic hematologic disorder stem cells, and analyzing the restraining effect of the medicines on the neoplastic hematologic disorder stem cells. According to the method for leukaemia high-flux medicine screening disclosed by the invention, in accordance with a patient, an appropriate treatment scheme and opinions can be accurately given in an individualizing manner, a valuable treatment opportunity is strived for the recurrent and refractory patient, reagent risk is reduced, the medicine curative effect is increased to the maximum degree, and medicine side effects are reduced to the maximum degree; and besides, pharmaceutical combinations can be performed, in accordance with clinical frequently-used chemotherapeutics combinations, comprehensive marking is performed, and a reference is provided for a doctor in the respect of formulating clinical united medication for the patient.

The invention discloses an antibody-drug conjugate of targeted CD45 and preparation and application thereof. By coupling a CD45 antibody with a drug, the targeted CD45 is used for highly selectively eliminating normal, diseased and cancerous immune cells. The antibody-drug conjugate of the targeted CD45 can be used for eliminating diseased or cancerous immune cells, replacing chemotherapeutic drugs and treating blood system diseases. The antibody-drug conjugate of the targeted CD45 only aims at the immune cells and cannot kill other active division cells, and the targeted elimination of an immune system can avoid graft-versus-host disease (GVHD), so that a large number of donor mature immune cells can be transplanted at the same time, and the immune system is quickly established.

Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

The invention discloses a traditional Chinese medicine composition used for treating malignant diseases of the blood system, containing the following 36 components in total: 10-30 parts of cockroach,25-45 parts of camptotheca acuminata decne, 2-6 parts of jequirity bean, 20-40 parts of Wulonggen, 20-40 parts of salvia miltiorrhiza, 25-45 parts of eupolyphaga, 2-5 parts of castor bean, 20-40 partsof lalang grass rhizome, 10-30 parts of hairyvein agrimony, 10-30 parts of caulophyllum robustum, 15-35 parts of glabrous sarcandra herb, 160-240 parts of gypsum, 15-35 parts of prunella vulgaris, 10-30 parts of morus australis, and the like. The composition is applied to malignant diseases of the blood system, can effectively kill cancer cells, and can achieve the clinical cure criterion, and disease cannot relapse after long-term follow-up.

The invention discloses application of a targeting STAT1 inhibitor in treatment of immune thrombocytopenia and a method. An STAT1 nuclear inhibitor ivermectin and an STAT1 activation inhibitor fludarabine are adopted, and the number of platelets of an immune thrombocytopenia mouse model is increased by injecting the activation inhibitor or the nuclear inhibitor. In the abovementioned way, the fludarabine is a fluorinated nucleotide analogue of arabinoside, is free of radioactivity and is a small-molecule phosphorylation inhibitor; meanwhile, the ivermectin is a small-molecule inhibitor introduced by an input protein alpha/beta 1 mediated cell nucleus, the ivermectin and the small-molecule inhibitor are high in bioavailability, are widely applied to treatment of various blood system diseases, are good in safety, are applied to treatment of the immune thrombocytopenia and are safe, effective and high in compliance.